Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2016-2023


The Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading healthcare companies.

Publication date
April 2023
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.


This report provides details of the latest co-development agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-development agreements from 2016 to 2023.


There is an increasing willingness for parties to enter co-development deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.


Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.


There are mainly two forms of co-development deals; Either the parties agree on a certain division of ownership, or decide that one party gets the rights to commercialise the drug in a certain geographical area, and the other side gets the other geographical area rights. Typically, the ownership division applies when it is likely that the project will be licensed at a later point in time. The geographical split usually applies when the two companies are determined to commercialise the drug themselves.


Another reason for co-development deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of co-development deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of co-development dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-development as well as a discussion on the merits of the type of deal.


Chapter 3 provides an overview of the structure of co-development deals. The chapter includes numerous case studies to enable understanding of both pure co-development deals and multicomponent deals where co-development forms a part.


Chapter 4 provides a review of the leading co-development deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.


Chapter 5 provides a comprehensive listing of the top 25 most active co-development dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.


Chapter 6 provides a comprehensive review of co-development financials for deals announced since 2016, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.


Chapter 7 provides a comprehensive and detailed review of co-development deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-development deal.


The appendices to the report includes a comprehensive listing of all co-development deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.


The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.


The report also includes numerous table and figures that illustrate the trends and activities in co-development dealmaking since 2016.


In conclusion, this report provides everything a prospective dealmaker needs to know about co-development alliances.


Key benefits


Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits:


  • In-depth understanding of co-development partnering deal trends since 2016
  • Analysis of the structure of co-development agreements with real life case studies
  • Comprehensive listing of all co-development deals since 2016, together with deal terms, value and press release
  • Comprehensive access to actual co-development contracts entered into by the world’s leading life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a co-development agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading life science companies worldwide.         


Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 includes:


  • Trends in co-development dealmaking in the biopharma industry since 2016
  • Analysis of co-development deal structure
  • Case studies of real-life co-development deals
  • Comprehensive listing of co-development deals since 2016
  • Access to co-development contract documents
  • Key financial bnchmarks for headline, upfront, milestone and royalty rates
  • The leading co-development deals by value since 2016
  • Most active co-development dealmakers since 2016
  • The leading co-development partnering resources


In Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 available deals and contracts are listed by:


  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type


Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.


The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to available contract documents for co-development deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2016-2023 provides the reader with the following key benefits:


  • In-depth understanding of co-development deal trends since 2016
  • Analysis of the structure of co-development agreements with real life case studies
  • Comprehensive listing of all co-development deals since 2016, together with deal terms, value and press release
  • Comprehensive access to actual co-development contracts entered into by the world’s life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a co-development agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Co-development dealmaking


2.1. Introduction

2.2. Definition of co-development deals

2.3. Success factors for co-development deals

2.4. When co-development can be useful

2.5. Attributes of co-development deals

2.6. Aligning partners to make the co-development work

2.7. Trends in Co-development deals since 2016

2.7.1. Co-development dealmaking by year, 2016 to 2023

2.7.2. Co-development dealmaking by phase of development, 2016 to 2023

2.7.3. Co-development dealmaking by industry sector, 2016 to 2023

2.7.4. Co-development dealmaking by therapy area, 2016 to 2023

2.7.5. Co-development dealmaking by technology type, 2016 to 2023

2.7.6. Co-development dealmaking by most active company, 2016 to 2023

2.8. Option to co-develop

2.9. The future of co-development deals


Chapter 3 – Overview of Co-development deal structure


3.1. Introduction

3.2. Pure versus multi-component co-development deals

3.3. Pure co-development agreement structure

3.3.1. Example co-development agreements

3.3.1.a. Case study 1

3.3.1.b. Case study 2


Chapter 4 – Leading Co-development deals


4.1. Introduction

4.2. Top Co-development deals by value


Chapter 5 – Top 25 most active Co-development dealmakers


5.1. Introduction

5.2. Top 25 most active Co-development dealmakers


Chapter 6 – Co-development deal term financials


6.1. Introduction

6.2. Co-development partnering headline values

6.3. Co-development deal upfront payments

6.4. Co-development deal milestone payments

6.5. Co-development royalty rates


Chapter 7 – Co-development deals including contracts directory


7.1. Introduction

7.2. Co-development deals with contracts 2016 to 2023




Appendix 1 – Co-development dealmaking by companies A-Z

Appendix 2 – Co-development dealmaking by industry sector

Appendix 3 – Co-development dealmaking by stage of development

Appendix 4 – Co-development dealmaking by therapy area

Appendix 5 – Co-development dealmaking by technology


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from Current Partnering




Figure 1: Definition of co-development

Figure 2: Situations where co-development can prove useful

Figure 3: Key components of a co-development deal

Figure 4: Issues in implementing co-development agreements

Figure 5: Trends in Co-development deal announcements, 2016 to 2023

Figure 6: Co-development deals signed at each phase of development, 2016 to 2023

Figure 7: Co-development deals by industry sector, 2016 to 2023

Figure 8: Co-development deals by therapy area, 2016 to 2023

Figure 9: Co-development deals by technology type, 2016 to 2023

Figure 10: Top 25 most active co-development dealmakers, 2016 to 2023

Figure 11: Co-development agreements – what should a contract include?

Figure 12: Components of the co-development deal structure

Figure 13: Top co-development deals by value 2016 to 2023

Figure 14: Most active Co-development dealmakers 2016 to 2023

Figure 15: Co-development deals with a headline value

Figure 16: Co-development deals with an upfront value

Figure 17: Co-development deals with a milestone value

Figure 18: Co-development deals with a royalty rate value

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1ST Biotherapeutics, 2seventy bio, 3B Pharmaceuticals, 3D-Micromac, 3DMed, 3D Systems, 4basebio Discovery, 10X Genomics, A*STAR Institute of Microelectronics (IME), A2A Pharmaceuticals, AAK, Abbisko Therapeutics, Abbvie, Abcam, AbCellera Biologics, Abiosciences, ABL Bio, Abpro, AbVacc, ABVC BioPharma, ACADIA Pharmaceuticals, Accelerate Technologies, Acceleron Pharma, Accellix, Accent Therapeutics, Accord Healthcare, ACEA Biosciences, Ache, AC Immune, Acoustic MedSystems, Acrivon Therapeutics, Adaptimmune, Aduro BioTech, Advaxis, Adventist Health, Adventus Ventures, Aerolase, Affibody, Affini-T Therapeutics, AFT Pharmaceuticals, Agena Bioscience, Agendia, Agilent Technologies, Agios Pharmaceuticals, AIkido Pharma, AiLife Diagnostics, Aimed Bio, Air Products, Ajinomoto, Akcea Therapeutics, Akoya Biosciences, Albany Molecular Research, Alcove Manufacturing and Distribution, Alector, Alexion Pharmaceuticals, Algenex, Alibaba Health, Align Technology, Alkem Laboratories, Allegheny Technologies, Allele Biotechnology and Pharmaceuticals, Alligator Bioscience, Allotex, Alnylam Pharmaceuticals, Alphamab Biopharmaceuticals, Alteogen, Alternavida, Altor BioScience, Altos Group, Alvotech, Alytas Therapeutics, Alzheimer's Drug Discovery Foundation, Amerimmune, Amgen, Amplifire, Amyris, AnchorDx, Andon, AnGes MG, AnHeart Therapeutics, Ankarys Therapeutics, Apellis Pharmaceuticals, Apobiologix, Apollomics, Applied StemCell, Aprecia Pharmaceuticals, Aptar Pharma, Aptevo Therapeutics, Aptorum Group, Aquestive Therapeutics, ARaymondlife, Arbele, Arbutus, Arcellx, Arcturus Therapeutics, Arcus Biosciences, Ardeagen, Arecor, Arrowhead Pharmaceuticals, Artes Biotechnology, Artios Pharma, Arvinas, Arzeda, Ascenion, Ascensia Diabetes Care, Ascentage Pharma, ASC Therapeutics, Asensus Surgical, ASKA Pharmaceuticals, Aspect Biosystems, Aspen Imaging Healthcare, Astellas Pharma, AstraZeneca, Athena Pharmaceutiques, Atomwise, Atropos Therapeutics, Augmenta, AUM Biosciences, Aurealis Therapeutics, Autotelic BIO, Avacta, Avactis Biosciences, Avalon GloboCare, Avellino Labs, Avicanna, Aviragen Therapeutics, Aviva Systems Biology, Axela, AXIM Biotechnologies, Axis Lighting, Azitra, Azos Bio, Bach Biosciences, Banyan Biomarkers, Battelle, Bayer, Beam Therapeutics, BehaVR, BeiGene, Beijing Defengrei Biotechnology, Beijing Sun-Novo Pharmaceutical Research, Belharra Therapeutics, Berry Genomics, Berry Oncology, Betta Pharmaceuticals, Beyondspring Pharmaceuticals, BGI Americas, Bharat Biotech, Biedermann Motech, Bill and Melinda Gates Foundation, Bio-Rad Laboratories, Bio-Techne, BioAtla, BioCanna Healthcare, Biocept, BioComo, BIOCORP, BiocurePharm, Biocytogen, Biodextris, BioGemex, Biogen, BioInvent, BioKey, BioLabs, Biolase, BioLegend, BIOMEDX Group, BioMotiv, Biomunex Pharmaceuticals, BioNano Genomics, BioNova Pharmaceuticals, Bionpharma, BioNTech, BiosanaPharma, BioSerenity, BioSun Pharmed, BioVaxys, Bioventus, Bird Foundation, Blackrock Microsystems, Blake Insomnia Therapeutics, Blau Pharma, Bloomios, Blueberries Medical, Bluebird Bio, Blueprint Medicines, Blue Water Vaccines, BodyLogicMD, Boehringer Ingelheim, Bolt Biotherapeutics, Boreal Genomics, Boryung Pharmaceutical, BreathTech, BrickBio, BridgeBio Pharma, Bridge Biotherapeutics, Brigham and Women's Hospital, BrighGene Biomedical, Bristol-Myers Squibb, Broad Institute, Bruker, Bruker Energy & Supercon Technologies (BEST), Burning Rock, Cactus Semiconductor, Cadila Pharmaceuticals, California Institute for Biomedical Research, Cambrooke Therapeutics, Can-Fite BioPharma, Cancer Genetics, CannaSoul Analytics, Cannassure Therapeutics, Canon BioMedical, Capsida Biotherapeutics, Captor Therapeutics, Caraway Therapeutics, CARB-X, Carbios, CardieX, Cardiff University, Cardiovascular Systems, Carina Biotech, Carl Zeiss, Carl Zeiss Meditec, CBT Pharmaceuticals, CEA-Leti, Cedars-Sinai Medical Center, Celgene, Cellastra, Cellgen Diagnostics, CellPoint, Celltrion, Cellular Biomedicine, Cellvera, Censa Pharmaceuticals, Center for Sensorimotor Neural Engineering, Central Institute for Experimental Animals, Cerenis Therapeutics, Cerulean Pharma, Champions Oncology, Charles River Laboratories, Cheil Pharm, ChemDiv, Chi-Med, China National Biotech Group (CNBG), Chinese Academy of Sciences, Chiome Bioscience, ChroMedX, CicloMed, Cidara Therapeutics, CimCure, Cipla, Ciron Drugs & Pharmaceuticals, ClearPoint Neuro, Cleveland Clinic, Clinical Study Support, CMDC Labs, Coave Therapeutics, Codagenix, Coeptis Pharmaceuticals, Coherus Biosciences, Collplant, Complement Pharma, Conductive Technologies, Confo Therapeutics, Context Therapeutics, Cosmo Pharmaceuticals, Covestro, CRISPR Therapeutics, CrystalGenomics, CSL, CStone Pharmaceuticals, CtM Biotech, Cue Biopharma, Cullinan Oncology, CURE Pharmaceutical, CureVac, CutisPharma, Cyagen Biosciences, Cygnus, CytomX Therapeutics, Dabur, Daewoong Pharmaceutical, Daiichi Sankyo, Dana-Farber Cancer Institute, Dance Biopharm, DaRui Biotech, Debiopharm, Deciphex, Definiens, Denali Therapeutics, Department of Defense, Department of Health and Human Services, DePuy, Dermavant Sciences, Diabeloop, Dicerna Pharmaceuticals, DigiLab, DotBio, Dow AgroFresh, Dr. Reddy's Laboratories, Dryworld, DSM, Duke-NUS Graduate Medical School Singapore, Dyadic International, eCential Robotics, EdgeEndo, EirGenix, Eisai, Elekta, Elektrofi, ElevateBio, EligoChem, Eli Lilly, Elite Pharmaceuticals, Elpis Biomed, Emergent BioSolutions, Emmaus Life Sciences, Empirico, Enigma Biomedical, Enko, Entasis Therapeutics, Enterome Bioscience, EpiVax Therapeutics, Especificos Stendhal, EspeRare Foundation, Esperovax, Essex Bio-Technology, Estee Lauder, Evercyte, Evidation Health, Evidera, Evosep, Evotec, EVQLV, Evvivax, Excelra, Exosome, Eybna Technologies, Eyegene, Fabric Genomics, FairJourney Biologics, Fannin, Farmacore Biotechnology, Fate Therapeutics, Ferrer International, FineImmune Biotechnology, Firebrand Therapeutics, Flowerkist, FlowJo, fluidIQ, Foghorn Therapeutics, Foresee Pharmaceuticals, Formosa Pharmaceuticals, Fosun Pharmaceutical, Foundation Medicine, Fresenius Kabi Pharmaceuticals, Frontier Medicines, Fusion Pharmaceuticals, Fuzionaire Radioisotope Technologies, FYR Diagnostics, G2 Speech, Galderma, GB Sciences, Gedeon Richter, GE Healthcare, Genentech, GeneQuantum Healthcare, Genethon, Genetic Analysis, Geninus, Genmab, Genome Institute of Singapore, Genomic Testing Cooperative, Genoptix, Genosity, GenScript Biotech, GensKey Medical Technology, Georgia State University Research Foundation (GSURF), Getein Biotech, Gicell, GigaMune, Gilead Sciences, Ginkgo BioWorks, Glatt Group, GlaxoSmithKline, Glimpse Group, Global Access Diagnostics, Global Antibiotic Research and Development Partnership, Global Dx, Glytherix, GMSbiotech, GoodRx, Great Bay Bio, Greenlight Biosciences, GTEC Holdings, Guangzhou Boji Medical Biotechnological, Guerbet, H.M. Pharma Consultancy, H3 Biomedicine, HalioDx, HaloVax, Hamlet Pharma, Hanmi Pharmaceutical, Happify Health, Harbour Antibodies, Harbour Biomed, Harvard University, HDT Bio, HeartBeam, Heartflow, HebeCell, HEC Pharm, Helsinn Healthcare, Helsinn Therapeutics, Henlius Biotech, HiFiBio, High Beauty, Hikma Pharmaceuticals, Histogen, Hitachi Chemical, HK inno.N, Hollister Biosciences, Horizon Discovery, Hoth Therapeutics, HTC ChemRar, Huami, Hufeland Klinikum, Hummingbird Bioscience, Hyloris Pharmaceuticals, Hypertrust, I-Dante, I-mab, i2c Pharmaceutical Services, IACTA Pharmaceuticals, IBA, iBio, IBM Watson Health, Icagen, IDbyDNA, Idorsia, Igentify, Iktos, Illumina, Immatics Biotechnologies, ImmBio, ImmunityBio, Immunocore, Immunovia, Imperial College London, Implant Surfaces, Impression Healthcare, Imricor Medical Systems, Incyte, Indivumed, Infervision, Infex Therapeutics, InflaRx, Innate Pharma, inno-train Diagnostik, Innovent Biologics, Inova Genomics Laboratory, Inovio Pharmaceuticals, Insilico Medicine, Insitro, InSitu Biologics, Institute of Microchemical Technology, Institut Gustave Roussy, Institut Pasteur, Intabio, Integrated Cannabis Company, IntelGenx, Intellia Therapeutics, International Flavors and Fragrances, Intravacc, Intuitive Surgical, InventisBio, inviCRO, Ionis Pharmaceuticals, iPharma, Ipsen, iTeos Therapeutics, Iwatani Group, Ix Therapeutics, Jabez Pharma, Jacobio Pharmaceuticals, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Tobacco, JCR Pharmaceuticals, Jeffrey Modell Foundation, JETA Molecular, Jiangsu Carephar Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu NHWA Pharmaceutical, Johns Hopkins University, Johnson & Johnson Innovation, JSR, Junshi Biosciences, Juntendo University, JustRight Surgical, Kaiku Health, Kainos Medicines, Kaken Pharmaceutical, Kalos Therapeutics, Kanabo Research, Karl Storz, Kartos Therapeutics, Kite Pharma, Klaria, Kleo Pharmaceuticals, KSQ Therapeutics, KT Corporation, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kyverna Therapeutics, Laboratoires Thea, Laekna, Lannett, Launch Therapeutics, Laxai Pharma, Lead Discovery Center, LegoChem Biosciences, Leon-nanodrugs, LEO Pharma, Les Laboratoires Servier, Leucid Bio, Leukemia & Lymphoma Society, LG Life Sciences, LianBio, LifeLabs Medical Laboratory Services, LifeLink Foundation, LifeLiver, Life Magnetics, LifeQ, LineaRx, Lipidor, Lipigon Pharmaceuticals, Livzon Pharmaceutical, LogicNets, Louisiana State University, Loxo Oncology, LTS Lohmann Therapie-Systeme, Lumen Biomedical, Lundbeck, Luye Pharma Group, Lyell Immunopharma, Lygos, Macrogen, MagForce, MAKScientific, MangoGen Pharma, MASORI Therapeutic, Massachusetts General Hospital, MaSTherCell, Max-Delbruck Center for Molecular Medicine, Maya Medical, Mayo Clinic, Mazor Robotics, McQuade Center for Strategic Research and Development, MD Anderson Cancer Center, Meatable, Mechelen, MediciNova, Medicover, Medidata Solutions, Medigen Biotechnology, Medigen Vaccine Biologics, MedImmune, Medocann Pharma, Medolife Rx, Medtronic, Medx, Medytox, Meihua International Medical Technologies, MEI Pharma, Melinta Therapeutics, Menarini, Mercachem, Merck and Co, Merck KGaA, Meridian Laboratories, Mersana Therapeutics, Merus, Merz, Mesoblast, Metabolon, Metagenomi, Metalabs, MetP Pharma, MGI Pharma, Microbiotix, Mie University, Millennium, Mirati Therapeutics, MiRTLE Medical, Mission Bio, Mission Health, Mobility Health, Mobvoi, Mochida Pharmaceutical, Moderna, Molecular Templates, Molnlycke Health Care, Mologen, Momenta Pharmaceuticals, Morphic Therapeutic, MorphoSys, Mount Sinai Medical Center, MRI Interventions, Multiplex Genomics, Mundipharma, Mundo Sano, Mydecine Group, MYOS, Nalagenetics, Nanion, Nankai Hospital, Nanomix, Nanommune, NanoSmart Pharmaceuticals, NanoString Technologies, NantKwest, Natera, National Cancer Institute, National Healthcare Services (NHS), National Immunobiological Company, National Institutes of Health, Navitor Pharmaceuticals, Ncardia, NEC, Nektar Therapeutics, Neo Gene Pharm, Neo Medical, Neptune Technologies & Bioressources, Neptune Wellness Solutions, Nestle Health Science, Neuracle Genetics, Neuraly, Neurochase, Neurocrine Biosciences, Neurophth Therapeutics, NeuroSigma, Newly Institute, Newsoara Biopharma, NextCure, NFL Biosciences, NGK Spark PLug, Nipro Corporation, Nkarta Therapeutics, Noile-Immune Biotech, Noramco, Norwegian University of Science, Notable Labs, NOTA Laboratories, Novartis, Novel351k, NovImmune, Novogene, Novoheart, Novo Nordisk, Novosound, Novozymes, Nuance Pharma, Numab, NuProbe, Nurix, NutriQuest, NuVasive, nView Medical, Ocean Genomics, Ocugen, Ocumension Therapeutics, Ohio State University, Olympus, Oncologie, Oncology Pharma, Oncology Venture, Oncozen, One BioMed, OnFace, ONK Therapeutics, Ono Pharmaceutical, Onward Therapeutics, Open Book Extracts, OPKO Health, Optum, Ordaos Bio, Oregon Health Sciences University, Orgenesis, Ori Biotech, Orion, Orthofix Medical, Osaka University, OSE Immunotherapeutics, Otsuka, Oxford BioMedica, Oxis International, P-Chip, Pacific Biosciences, PACT Pharma, Paige, Pairnomix, Palisade Bio, Pall Corporation, Panaxium, Pasithea Therapeutics, Pathalys Pharma, PathGroup, PAVmed, PDS Biotechnology, Pebble Labs, PeptiDream, Perlara, Personal Genome Diagnostics, Pfizer, PharmaTher, PhaseBio Pharmaceuticals, PHC, Phillips-Medisize, Phlow, PhoreMost, Phylloceuticals, Pieris Pharmaceuticals, Pierre Fabre, Pleco Therapeutics, Plexium, Polyphor, Portal Bioscience, Praj Industries, Precise Biometrics, Precision NanoSystems, Premier Inc, Prestige BioPharma, PreventionGenetics, ProBioGen, Procare Health, Project to Accelerate New Treatments for Tuberculosis, Promethera Biosciences, Promore Pharma, Propeller Health, Protea Biosciences, Protein Metrics, Protein Sciences, ProteoMediX, Proteovant Therapeutics, Provention Bio, Pulmatrix, Pulmodyne, Purdue Pharma, Pure Extracts Technologies, Pure Protein, QED Therapeutics, Qiagen, Qilu Pharmaceutical, Quadira Biosciences, Qualcomm, Quantum-Si, Quark Pharmaceuticals, Quratis, Radiomedix, Rainbow Medical, Rakuten Medical, Rambam Medical Center, Ramot at Tel Aviv University, Rebus Biosystems, RedHill Biopharma, Redlen Technologies, RefleXion Medical, Refuge Biotechnologies, Regen BioPharma, Regeneron Pharmaceuticals, RemeGen, Rennovia, Repare Therapeutics, Replicel Life Sciences, Research Council of Norway, Resolve Biosciences, RespireRx Pharmaceuticals, Retrophin, ReveraGen BioPharma, Reyon Pharmaceuticals, Rgene, Rigel Pharmaceuticals, RightEye, Roche, Roche Diagnostics, Rocket VR Health, Roivant Sciences, RoosterBio, Rosalind, Rouumtech, Royal Philips Electronics, Sajo Consulting, Salus Pharma, Samsung Biologics, Sandoz, Sanford Health, Sanofi, Santen Pharmaceutical, Sarepta Therapeutics, SATT Paris-Saclay, SBRI Healthcare, Scandinavian Health, Scandion Oncology, Schrodinger, SciClone Pharmaceuticals, Scienion, SCM Pharma, Scorpion Therapeutics, Scottish Enterprise, Seagen, Seattle Genetics, Secarna Pharmaceuticals, Seikagaku, Seipasa, Selvita, Semtech, Sen-Jam Pharmaceutical, Senai Cimatec, Sensifree, Sensorion, Sentieon, Sentinel Oncology, SequMed, Seracare Life Sciences, Serum Institute of India, SFJ Pharmaceuticals, Shandong Boan Biological Technology, Shandong Luoxin Pharma, Shanghai Institute of Materia Medica, Sheba Medical Center, Shimadzu, Shuwen Biotech, Siemens Healthineers, Simcere Pharmaceuticals, Similis Bio, Sinergium Biotech, Sino Biological, SINTX Technologies, Sirenas, Sirnaomics, SiSaf, SkylineDX, Smartwise, SN BioScience, Sofregen Medical, Soitec, SomaLogic, Sonova, Sorrento Therapeutics, Sosei, Spencer Health Solutions, Spineart, STADA Arzneimittel, Staidson (Beijing) BioPharmaceuticals, Stealth BioTherapeutics, StemoniX, Stempeutics, SteriLumen, Stockton Group, Stoke Therapeutics, Stora Enso, Storm ID, StrideBio, Striiv, Sublime Stericeuticals, Sumitomo Dainippon Pharma, SunGen, Sunny Pharmtech, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Sutro Biopharma, Swedish Bactiguard, Swedish Orphan Biovitrum, Symbasis, Synaptive Medical, Synchronous Health, Syngenta, Synpromics, SynShark, SyntheticMR, Sysmex, Tachyon Therapeutics, Tactical Relief, Taiho, TaiwanBio Therapeutics, TaiwanJ Pharmaceuticals, Takeda Pharmaceutical, Takis Biotech, TALLC, Tangible Science, Tango Therapeutics, Tarveda Therapeutics, Tavotek Biotherapeutics, TC BioPharm, Teijin, Telix Pharmaceuticals, Terumo, Tetra Bio-Pharma, Texas A&M University, TFF Pharmaceuticals, TG Therapeutics, The Nutraceutical Medicine Company, Therapyx, Theravance, Therawis Diagnostics, Thermo Fisher Scientific, ThinkCyte, Tianjin CanSino Biotechnology, Tilray, Tissue Analytics, Tobii Technology, TOMA Biosciences, Torii Pharmaceutical, Torrey Pines Investment, Transgene, Translational Software, Transplant Genomics, Treventis, Triplebar Bio, Triple Ring Technologies, TrovaGene, Trovita Health Science, TRPharm, TSRL, Turnstone Biologics, Twist Bioscience, TYG Oncology, UbiQ, UCB, UGISense, Ultivue, Ultragenyx Pharmaceuticals, Umami Meats, Uni-Bio Science, United Therapeutics, Univercells, Universal Cells, University Hospital of Leuven, University of Bonn, University of California, San Diego, University of Copenhagen, University of Glasgow, University of Heidelberg, University of Massachusetts Medical School, University of North Texas, University of Ottawa, University of Surrey, Univo Pharmaceuticals, Vaccitech, Valent Biosciences, Validogen, Valneva, Vasomune Therapeutics, Vaximm, Vaxine, VeChain, Vect-Horus, VectorBuilder, Velabs Therapeutics, VenatoRx, Ventana Medical Systems, Veranome Biosystems, Veraxa Biotech, Vertex Pharmaceuticals, ViaCyte, Vical, Vici Health Sciences, Vifor-Fresenius Medical Care Renal Pharma, Virbac, Vir Biotechnology, Visiopharm, Visualant, Vium, vivoPharm, Voltron Therapeutics, Voluntis, Voyager Therapeutics, VSP Optics, Vyant Bio, VyGen-Bio, Wanchunbulin, WAVE Life Sciences, Weill Cornell Medical College, WellDoc, Wellmarker Bio, Westlake Pharma, Willow Biosciences, W L Gore, WuXi Biologics, Wyss Institute, X4 Pharmaceuticals, Xbiome, Xbrane Bioscience, Xencor, Xenon Pharmaceuticals, XERIS Pharmaceuticals, Xortx Therapeutics, Xylonix, Yabao Pharmaceutical, Yatiri Bio, Yingli Pharma, Yisheng Biopharma, YOFOTO (China) Health Industry, Yonsei University Severance Hospital, Yuhan Corporation, Yunnan Walvax Biotech, YVY Life Sciences, ZAI Laboratory, Zealand Pharma, Zebra Medical Vision, Zepp Health, Zivo Bioscience, Zylo Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!